The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income from continuing operations | 48,578 |
| Share-based compensation | 16,396 |
| Depreciation and amortization | 14,881 |
| Deferred income taxes | -8,710 |
| Credit loss expense | 6,515 |
| Non-cash lease expenses | 1,262 |
| Shares received in settlement of litigation | 0 |
| Loss on extinguishment of debt | 0 |
| Other | 641 |
| Accounts receivable | 26,394 |
| Inventory | 1,533 |
| Other assets | 8,818 |
| Accounts payable | 2,119 |
| Accrued compensation | 8,986 |
| Accrued expenses | 2,371 |
| Other liabilities | 289 |
| Net cash flows from operating activities of continuing operations | 74,003 |
| Net cash flows used in operating activities of discontinued operations | 0 |
| Net cash flows provided by operating activities | 74,003 |
| Cash paid for acquisitions | 3,764 |
| Purchases of equipment | 1,033 |
| Other investments | 2,089 |
| Net cash flows used in investing activities | -6,886 |
| Stock repurchased for tax withholdings on vesting of restricted stock | 3,118 |
| Cash paid for profit share payment (note 14) | 1,294 |
| Proceeds from citizens revolving credit facility | 0 |
| Proceeds from citizens term loan | 0 |
| Prepayment premium on previous term loan | 0 |
| Deferred financing cost | 0 |
| Repayment of previous term loan | 0 |
| Repayment of citizens revolving credit facility | 0 |
| Principal payments on citizens term loan facility | 1,000 |
| Proceeds from exercise of stock options | 0 |
| Repurchase of series b preferred shares | 0 |
| Other | 0 |
| Net cash flows used in financing activities | -5,412 |
| Net change in cash | 61,705 |
| Cash and cash equivalents, beginning of period | 104,416 |
| Cash and cash equivalents, end of period | 166,121 |
MIMEDX GROUP, INC. (MDXG)
MIMEDX GROUP, INC. (MDXG)